Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 41 - 50 of 155

Selected Filters:
20 August 2024

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.

Community/Advocacy, Research, Service Delivery

Document
15 August 2024

WHO Global PrEP Network – Destination Prevention: New Guidance for PrEP and PEP

This 90-minute webinar is intended for communities, providers, policy makers and advocates for PrEP, PEP and HIV prevention. We will provide an overview of the key takeaways and new guidance from newly released WHO PrEP Implementation Tool: Provider Module for Oral and Long Acting PrEP and the 2024 Guidelines on HIV Post-Exposure Prophylaxis. We will…

Normative Guidance/Policies, Service Delivery

Event
5 August 2024

Client Experiences with “Dynamic Choice Prevention,” a Model for Flexible Patient-centred HIV Prevention Delivery in Rural Eastern Africa

This article from Journal of the International AIDS Society discusses client experiences of a dynamic choice model for HIV prevention piloted in Kenya and Uganda under the SEARCH study, where clients were supported to select HIV prevention method, testing mode, and service delivery channel from a range of options.

Research, Service Delivery

External Link
19 July 2024

Coordinating Implementation Science for CAB for PrEP: HIV Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss emerging issues around cabotegravir (CAB) for PrEP implementation and HIV testing algorithms.

Research, Service Delivery, Testing

Document
16 July 2024

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…

Research, Service Delivery

Document
11 July 2024

CAB PrEP Introduction Supply Chain Considerations – Kenya 2023

This document summarizes considerations for the integration of CAB PrEP within Kenya’s supply chain system based on interview with key national and subnational stakeholders.

Normative Guidance/Policies, Research

Document
8 July 2024

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention programs. In the…

Monitoring & Evaluation

Presentation
14 June 2024

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.

Community/Advocacy

Presentation
10 June 2024

HPTN 083-02: Factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

This article from Journal of the International AIDS Society to explores the experiences of participants in the HPTN-083 trial, which evaluated safety and efficacy of cabotegravir for PrEP, including barriers to adherence and other factors that may have impacted study implementation or outcomes.

Research

External Link
3 June 2024

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Slides / Recording Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention…

Service Delivery

Event